203 related articles for article (PubMed ID: 29039686)
21. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1998 Jan; 47(RR-2):1-30. PubMed ID: 9461044
[TBL] [Abstract][Full Text] [Related]
22. Tolerance of the newborn to antiretroviral drug exposure in utero.
Sibiude J; Warszawski J; Blanche S
Expert Opin Drug Saf; 2015 May; 14(5):643-54. PubMed ID: 25727366
[TBL] [Abstract][Full Text] [Related]
23. HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
Ton Q; Frenkel L
Curr HIV Res; 2013 Mar; 11(2):126-36. PubMed ID: 23432488
[TBL] [Abstract][Full Text] [Related]
24. Management of HIV infection during pregnancy.
McGowan JP; Shah SS
Curr Opin Obstet Gynecol; 2000 Oct; 12(5):357-67. PubMed ID: 11111877
[TBL] [Abstract][Full Text] [Related]
25. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.
Mofenson LM;
MMWR Recomm Rep; 2002 Nov; 51(RR-18):1-38; quiz CE1-4. PubMed ID: 12489844
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of HIV therapies in pregnant patients: an update.
Neary M; Owen A; Olagunju A
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):449-461. PubMed ID: 32271621
[TBL] [Abstract][Full Text] [Related]
27. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
Thorne C; Newell ML
Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
[TBL] [Abstract][Full Text] [Related]
28. Treating HIV during pregnancy: an update on safety issues.
Watts DH
Drug Saf; 2006; 29(6):467-90. PubMed ID: 16752931
[TBL] [Abstract][Full Text] [Related]
29. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
Suksomboon N; Poolsup N; Ket-Aim S
J Clin Pharm Ther; 2007 Jun; 32(3):293-311. PubMed ID: 17489882
[TBL] [Abstract][Full Text] [Related]
30. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Guay LA; Musoke P; Fleming T; Bagenda D; Allen M; Nakabiito C; Sherman J; Bakaki P; Ducar C; Deseyve M; Emel L; Mirochnick M; Fowler MG; Mofenson L; Miotti P; Dransfield K; Bray D; Mmiro F; Jackson JB
Lancet; 1999 Sep; 354(9181):795-802. PubMed ID: 10485720
[TBL] [Abstract][Full Text] [Related]
31. [Antiviral agents for reduction of mother-to-child transmission of HIV infection].
Bruun JN
Tidsskr Nor Laegeforen; 2003 Aug; 123(15):2041-2. PubMed ID: 12934126
[No Abstract] [Full Text] [Related]
32. Antiretroviral pharmacology: special issues regarding pregnant women and neonates.
Mirochnick M; Best BM; Clarke DF
Clin Perinatol; 2010 Dec; 37(4):907-27, xi. PubMed ID: 21078458
[TBL] [Abstract][Full Text] [Related]
33. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Boivin MJ; Maliwichi-Senganimalunje L; Ogwang LW; Kawalazira R; Sikorskii A; Familiar-Lopez I; Kuteesa A; Nyakato M; Mutebe A; Namukooli JL; Mallewa M; Ruiseñor-Escudero H; Aizire J; Taha TE; Fowler MG
Lancet HIV; 2019 Aug; 6(8):e518-e530. PubMed ID: 31122797
[TBL] [Abstract][Full Text] [Related]
34. Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
Capretti MG; Marsico C; Conti M; Corvaglia LT; Arcuri S; Faldella G; Re MC
New Microbiol; 2016 Oct; 39(4):314-316. PubMed ID: 27284987
[TBL] [Abstract][Full Text] [Related]
35. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Venkatesh KK; Farhad M; Fenton T; Moodley D; Naik S; Nakabiito C; Fairlie L; Fowler MG; Stringer JSA; Chi BH
AIDS; 2019 Dec; 33(15):2403-2413. PubMed ID: 31764105
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
Bhana N; Ormrod D; Perry CM; Figgitt DP
Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
[TBL] [Abstract][Full Text] [Related]
37. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
Mirochnick M; Siminski S; Fenton T; Lugo M; Sullivan JL
Pediatr Infect Dis J; 2001 Aug; 20(8):803-5. PubMed ID: 11734746
[TBL] [Abstract][Full Text] [Related]
38. Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues.
Thorne C; Newell ML
Med Wieku Rozwoj; 2003; 7(4 Pt 1):425-36. PubMed ID: 15010553
[TBL] [Abstract][Full Text] [Related]
39. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P;
BMC Infect Dis; 2012 Oct; 12():246. PubMed ID: 23039034
[TBL] [Abstract][Full Text] [Related]
40. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
